Polarean Imaging achieves positive phase III results in two clinical trials

Polarean Imaging PLC (LON:POLX) CEO Richard Hullihen tells Proactive its two phase III clinical trials have 'demonstrated handily' that its technology allows doctors and surgeons to visualize aspects of lung function that have gone undetected using traditional magnetic resonances imaging (MRI) techniques. Hullihen says Polarean expects to submit a new drug application (NDA) for its drug/device in the third quarter, after a pre-NDA meeting with the FDA.